A PYMNTS Company

Chile: Pfizer affiliate rejects accusations of market power abuses

By  |  August 2, 2016

G.D. Searle LLC, a Chilean subsidiary of pharma giant Pfizer, has responded to accusations by the country’s economic prosecutors, the FNE, and the country’s Tribunal for the Defense of Free Competition (TDLC), rejecting claims of market power abuse in the sale and placement of medicines containing the Celecoxib active ingredient, dominated by the brand’s Celebra formula.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The response, filed by Chilean attorney Guillermo Carey, states that “the FNE’s assessments are incorrect, and suffer from serious vices that lay bare a lack of understanding of the patent medicine system, which totally undermine the argument presented.” The statement clarifies that the conducts being denounced by the economic regulator as exclusionary and abusive are in fact “correspondent to the legitimate enforcement of G.D. Searle’s right to obtain – and then to defend- a currently valid patent protection.”

    The statement emphasizes that their patent protection was granted through legitimate means. Furthermore, the company states, this protection has not only been granted in Chile, but also in several other countries such as Japan, Australia, Canada, China and India, where “it enjoys active, peaceful protection.”

    Full Content: Economía y Negocios

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.